What Changes When Your Program Crosses Into Commercial
There's a moment in every biotech's journey that doesn't get marked on the Gantt chart. It's the moment when the supply chain shifts from supporting clinical development to preparing for commercial reality — and almost everything about how the organization operates needs to change with it.
I've been through this transition multiple times, from different seats and at different kinds of companies. And what strikes me every time is how much of the shift is invisible until you're in the middle of it. The science doesn't change. The molecule is the same. But the infrastructure around it — the expectations, the pace, the margin for error — transforms completely.
The Operational Reality
In clinical supply, the operating model is built around flexibility. Batch sizes are smaller. Timelines are driven by trial enrollment. If something goes wrong, you have room to troubleshoot, adjust, remanufacture. The consequences of a delay are real, but they're usually measured in weeks, not revenue.
Commercial flips that entirely. Suddenly you're manufacturing to a demand forecast, not a clinical protocol. You need supply continuity — not just successful batches, but a reliable, repeatable cadence of them. Your supply plan has to account for safety stock, shelf life management, and distribution timing across potentially dozens of markets. The tolerance for disruption shrinks dramatically, and the financial exposure on every batch goes up.
What surprises most teams isn't any single new requirement. It's the sheer number of parallel workstreams that have to come online at roughly the same time. Packaging and labeling for commercial presentation. Serialization and track-and-trace compliance. Shipping lane qualifications. Cold chain validation. State licensing. Quality agreements with new commercial partners. Each one has its own timeline, its own dependencies, and its own potential to become a bottleneck. In clinical, these either didn't exist or were handled in a simplified form. In commercial, they're all critical path.
The Organizational Shift
The operational complexity is one thing. The organizational shift is harder to see and, in my experience, harder to get right.
In the clinical phase, supply chain often operates as a small, scrappy team — sometimes a single person — embedded within a development-focused organization. Decisions are made quickly, informally, and with a lot of individual judgment. That works when you're managing a handful of manufacturing campaigns and a few key vendor relationships.
Commercial demands something different. Not necessarily a massive team, but a fundamentally different way of working. Cross-functional coordination becomes non-negotiable — supply chain has to be in lockstep with commercial forecasting, quality, regulatory, and finance in ways that simply weren't required before. Processes that lived in someone's head or in a spreadsheet need to be documented, repeatable, and auditable. The organization has to shift from a culture of "figure it out" to a culture of "build the system."
This is where I've seen the most friction. Not because people resist the change, but because the clinical-stage operating model was successful — it got the company to this point. Letting go of what worked to build something new, while simultaneously running at full speed toward a launch, is genuinely hard. And it requires leadership to recognize that the skills and structures that got you through Phase III are not the same ones that will sustain a commercial product.
What I've Seen Work
The companies that navigate this transition well tend to share a few things in common.
They start early. Not early in the "we mentioned it at a board meeting" sense, but early in the "we have a dedicated person or team thinking about commercial supply chain 18 to 24 months before anticipated approval" sense. That lead time isn't a luxury. It's the minimum needed to stand up the infrastructure without cutting corners that come back to hurt you.
They invest in the right kind of experience. This transition has been done before. Companies that bring in people who've been through it — whether as hires or as outside advisors — avoid the most painful learning curves. It's not about replacing the team that got you here. It's about augmenting it with people who know what's coming.
They treat the transition as an organizational evolution, not just a supply chain project. When leadership frames commercial readiness as a company-wide shift rather than a supply chain workstream, it gets the cross-functional attention and resources it needs. When it's treated as supply chain's problem to solve alone, things fall through the cracks — and they tend to fall at the worst possible time.
And they're honest about what they don't know. The most dangerous assumption in this transition is that clinical success means commercial readiness. It doesn't. They're related but fundamentally different challenges, and the companies that acknowledge that gap early are the ones that close it in time.
The Transition Nobody Warns You About
If there's one thing I'd want someone approaching this moment to hear, it's this: the clinical-to-commercial transition isn't a phase. It's a transformation. It touches your operations, your team structure, your partner relationships, your systems, and your organizational culture. And it happens while you're simultaneously trying to get a product approved and launched.
It's one of the most demanding stretches in the life of a biotech company. It's also one of the most rewarding — because on the other side of it, you're not just a development-stage company anymore. You're delivering a therapy to patients. Everything changes to make that possible, and it's worth getting right.
Verant Consulting Group partners with biotech companies navigating the clinical-to-commercial transition — helping build the supply chain infrastructure, team capabilities, and partner relationships needed to launch successfully. Let's talk about where you are in the journey.